The Additive Effect of Topical Dorzolamide-Timolol with Intravitreal Ranibizumab Injection in Diabetic Macular Edema

Gadwal, Sara; Madbouly, Wafaa A.; Mansour, Mona

doi:10.21608/aimj.2022.166168.2216

Cited by 2 publications

(2 citation statements)

References 19 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Badawi et al suggested that topical dorzolamide without IVB injection can be effective in CMT reduction and BCVA improvement (11). Three other studies have investigated the e cacy of topical aqueous suppressants combined with intravitreal anti-VEGF injection in treating DME (12,13,18). Fazel et al…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical dorzolamide as adjunctive treatment with intravitreal bevacizumab in bilateral diabetic macular edema

Sadr,

Sargazi,

Banaie

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is accepted as the gold standard treatment for center-involving diabetic macular edema (CI-DME). Adjunctive administration of topical dorzolamide may enhance the therapeutic effects of anti-VEGF agents. In this study, we compared the efficacy of topical dorzolamide plus intravitreal injection of bevacizumab (IVB) versus IVB alone in patients with bilateral DME. Methods: This randomized, double-blind, contralateral eye study included 50 eyes of 25 patients with bilateral DME. All eyes received three consecutive monthly injections of IVB. For each patient, one eye was randomized to instill dorzolamide eye drops three times a day as an intervention, and the other received artificial tear drops as a placebo. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were evaluated before starting treatment and then monthly for the first 3 months. Results: Among 25 included patients, the average age was 56.64 ± 7.97 years, and 48% were female. BCVA did not improve significantly in any groups (P>0.05). No significant difference was observed in terms of BCVA between the intervention and control groups (P>0.05). The present study showed a decrease in CMT in both study groups (P<0.05). At month 3, the decrease in mean CMT from baseline was significantly higher in eyes receiving topical dorzolamide compared to the control group (-88.92 ± 82.90 vs -37.64 ± 86.16 µM, respectively; P = 0.037). IOP decreased significantly only in eyes receiving dorzolamide (P<0.001). Conclusions: The results of the present study indicate that adjunctive administration of topical dorzolamide has a beneficial effect on CMT reduction from baseline but it did not have an additive effect on BCVA improvement Compared to IVB monotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Mirshahi et al reported a decrease in CMT and improvement in BCVA by adding timolol-dorzolamide eye drop to IVB injection (13). In 2022, a prospective cohort study indicated that adding topical dorzolamide-timolol as an adjuvant of intravitreal ranibizumab injection (IVR) has no statistically signi cant bene ts (18).…”

Section: Discussionmentioning

confidence: 99%

Topical dorzolamide as adjunctive treatment with intravitreal bevacizumab in bilateral diabetic macular edema

Sadr,

Sargazi,

Banaie

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Topical Dorzolamide as Adjunctive Treatment With Intravitreal Bevacizumab in Bilateral Diabetic Macular Edema

Sadr,

Sargazi,

Banaie

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is accepted as the gold standard treatment for center-involving diabetic macular edema (CI-DME). Adjunctive administration of topical dorzolamide may enhance the therapeutic effects of anti-VEGF agents. In this study, we compared the efficacy of topical dorzolamide plus intravitreal injection of bevacizumab (IVB) versus IVB alone in patients with bilateral DME. Methods: This prospective, randomized contralateral eye study was carried out in a tertiary referral ophthalmology center, Al-Zahra Eye Hospital, Zahedan, Iran, between April 2021 and April 2022. This study included 50 eyes of 25 patients with bilateral DME. All eyes received three consecutive monthly injections of IVB. For each patient, one eye was randomized to instill dorzolamide eye drops three times a day as an intervention, and the other received artificial tear drops as a placebo. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were evaluated before starting treatment and then monthly for the first three months. Results: Among 25 included patients, the average age was 56.64 ± 7.97 years, and 48% were female. BCVA did not improve significantly in any groups (P > 0.05). No significant difference was observed in terms of BCVA between the intervention and control groups (P > 0.05). The present study showed a decrease in CMT in both study groups (P < 0.05). At month 3, the decrease in mean CMT from baseline was significantly higher in eyes receiving topical dorzolamide compared to the control group (-88.92 ± 82.90 vs. -37.64 ± 86.16 µM, respectively; P = 0.037). IOP decreased significantly only in eyes receiving dorzolamide (P < 0.001). Conclusions: The results of the present study indicate that adjunctive administration of topical dorzolamide has a beneficial effect on CMT reduction from baseline, but it did not have an additive effect on BCVA improvement compared to IVB monotherapy.

show abstract

The Additive Effect of Topical Dorzolamide-Timolol with Intravitreal Ranibizumab Injection in Diabetic Macular Edema

Cited by 2 publications

References 19 publications

Topical dorzolamide as adjunctive treatment with intravitreal bevacizumab in bilateral diabetic macular edema

Topical dorzolamide as adjunctive treatment with intravitreal bevacizumab in bilateral diabetic macular edema

Topical Dorzolamide as Adjunctive Treatment With Intravitreal Bevacizumab in Bilateral Diabetic Macular Edema

Contact Info

Product

Resources

About